• Publications
  • Influence
Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies
TLDR
The addition of N-acetyl l-cysteine to the cultures markedly increased the expansion of T cells from human peripheral blood mononuclear cells without diminishing cell function and indicated that T cell-stimulating effects of anti-CD3/anti-CD28 beads can be further manipulated to control the Expansion of antigen-specific memory T cells. Expand
Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma.
TLDR
Three studies suggest that CD34+ marrow cells are capable of reconstituting hematopoiesis in humans, and five patients showed durable engraftment until the time of death 82 to 386 days posttransplant. Expand
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
TLDR
The results suggest that vasculogenesis in human MM may develop from tumoral production of PTN, which orchestrates the transdifferentiation of monocytes into VECs. Expand
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a
TLDR
This phase III trial demonstrates that although CD34 selection significantly reduces myeloma cell contamination in PBPC collections, no improvement in disease-free or overall survival was achieved. Expand
A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
TLDR
Adoptive immunotherapy with Xcellerated T Cells and IL-2 can be carried out safely on an outpatient basis in patients with advanced RCC, and there was a trend to increased postinfusion survival in patients achieving higher peak absolute lymphocyte counts. Expand
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
TLDR
The data indicate that chemotherapy plus G-CSF-mobilized PBPCs from cancer patients can be effectively expanded ex vivo and suggest the feasibility of large-scale expansion ofPBPCs, starting from small numbers of PB CD34+ cells. Expand
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
TLDR
It is suggested that mobilized PB cells may be preferable to BM for gene therapy applications and that progeny of mobilized peripheral blood cells can contribute long-term to engraftment of multiple lineages. Expand
Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells.
TLDR
Human bone marrow-derived CD34+ cells were analyzed for the expression of the beta 1-family of integrin adhesion molecules to identify an adhesion mechanism of potential importance in the localization of primitive progenitors within the hematopoietic microenvironment. Expand
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
TLDR
This phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy. Expand
Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation.
TLDR
The studies demonstrated that CD34 selection was necessary to obtain large, clinically relevant numbers of hematopoietic progenitors, and the addition of G-CSF to the baseline regimen of SCF/il-3/IL-6 significantly enhanced the expansion of myeloid progenitor cell expansion. Expand
...
1
2
3
4
5
...